Author:
Pezaro Carmel,Rosenthal Mark A.,Gurney Howard,Davis Ian D.,Underhill Craig,Boyer Michael J.,Kotasek Dusan,Solomon Benjamin,Toner Guy C.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference24 articles.
1. The epidermal growth factor receptor and its inhibition in cancer therapy.;Woodburn;Pharmacol Ther,1999
2. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate.;Sherwood;World J Urol,1995
3. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.;Torring;Anticancer Res,2000
4. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.;Di Lorenzo;Clin Cancer Res,2002
5. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.;Vicentini;J Cancer Res Clin Oncol,2003